Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

Dual anti-platelet therapy remains a cornerstone of the treatment for coronary artery disease. When choosing a second anti-platelet, ticagrelor remains a principal agent after the recent PLATO trial ...

A new study co-written by a University of Illinois Urbana-Champaign expert in operations management finds that drugs approved ...

Discover our testers’ and sleep experts' favorite pillows for back sleepers, including the best down, memory foam, wedge, and ...